Huahai Pharmaceutical announced that the company's net profit attributable to shareholders of listed companies for the first quarter of 2024, after deducting non-recurring profit and loss, is expected to be between RMB 292.2 million and RMB 30.5 million. Compared with the same period of the previous year (statutory disclosure data), it will increase by about 103.65 million yuan to 131.95 million yuan, an increase of about 55% to 70% over the previous year.